FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular, to novel mutants of streptokinase. Claimed are both mutant streptokinase polypeptides and fusion proteins, possessing streptokinase activity. Claimed streptokinases are included into formulations of pharmaceutical compositions, suitable for treatment of blood circulation diseases, in particular thromboses.
EFFECT: invention makes it possible to obtain more effective mutant polypeptides with streptokinase activity in treatment of blood circulation diseases.
20 cl, 37 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROTEINS SPECIFIC FOR CD137 | 2016 |
|
RU2736312C2 |
| NOVEL SPECIFIC BINDING POLYPEPTIDES AND ROUTES OF USE THEREOF | 2015 |
|
RU2723034C2 |
| NOVEL PROTEINS SPECIFIC FOR ANGIOGENESIS | 2016 |
|
RU2720688C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| FUSED POLYPEPTIDE WITH ANTICANCER ACTIVITY | 2016 |
|
RU2727165C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| THROMBOLYTICS FOR INTRAVASCULAR THROMBI | 2020 |
|
RU2822136C1 |
| IGG4 Fc FRAGMENT CONTAINING A MODIFIED HINGE REGION | 2014 |
|
RU2800558C1 |
| ANTIBODIES WITH CYSTEINE SUBSTITUTIONS OBTAINED BY GENETIC ENGINEERING AND THEIR CONJUGATES | 2011 |
|
RU2755066C2 |
| MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3) | 2016 |
|
RU2756318C2 |
